Experimental group:Qingda granules + Valsartan capsule simulation agent: Qingda granules 1 bag/time, 2 times/day

2 trials

Sponsors

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences

Conditions

hypertension

Early Phase 1

Clinical efficacy evaluation of Qingda Granule in the treatment of hypertension (grade 1, low to medium-risk) patients: a multicenter, randomized, double-blind, double-simulated, parallel-controlled, non-inferiority clinical study

RecruitingITMCTR2000003400

Xiyuan Hospital, Chinese Academy of Chinese Medical Scienceshypertension

Start: 2020-06-01Updated: 2023-02-20

Clinical efficacy evaluation of Qingda Granule in the treatment of hypertension (grade 1, low to medium-risk) patients: a multicenter, randomized, double-blind, double-simulated, parallel-controlled, non-inferiority clinical study

RecruitingChiCTR2000033890

Xiyuan Hospital, Chinese Academy of Chinese Medical Scienceshypertension

Start: 2020-06-01Updated: 2020-06-22

Related Papers

Efficacy and safety of Qingda granule versus valsartan capsule in Chinese grade 1 hypertensive patients with low-moderate risk: A randomized, double-blind, double dummy, non-inferiority, multi-center trial.

2024-01-043 citations

Effects of Qingda granule on patients with grade 1 hypertension at low-medium risk: study protocol for a randomized, controlled, double-blind clinical trial.

2023-01-023 citations